Does BPC-157 act on growth hormone receptors?

Effects related to growth hormone receptor expression have been reported in tendon fibroblast work. Whether that is an initiating event or downstream of something else is not established.

Why is the absence of a receptor such a problem?

Without knowing where the compound acts first, any downstream finding is a position in a chain of unknown length rather than a mechanism.

Does this mean BPC-157 promotes growth?

No. The observations concern signalling components in model systems, not growth or repair in an organism.

BPC-157 and Growth Factor Signalling

The short answer

Reported interactions with growth-factor signalling form part of BPC-157's multi-pathway description, including effects related to growth hormone receptor expression in tendon fibroblast work. Without an identified receptor for the peptide itself, these remain observations rather than a mapped mechanism.

Key facts

Reported: Effects on growth-factor signalling
Context: Tendon fibroblast and repair models
Peptide receptor: None identified
Interpretation: Downstream observation, not initiating event
Evidence type: In vitro and rodent
Independent replication: Limited

What is reported

Work in tendon fibroblast systems has reported effects related to growth hormone receptor expression, and the broader literature describes interactions with growth-factor signalling more generally. These sit within the multi-pathway framing rather than constituting a separate mechanism.

The interpretive problem

An effect on growth-factor signalling can be an initiating event or a downstream consequence of something else entirely. Distinguishing them requires knowing where the compound acts first, and no receptor for BPC-157 has been identified. Without that anchor, a reported change in a signalling pathway is a position in a chain of unknown length rather than a starting point.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £15.99

Why this recurs across the category

It is the same limitation described in the mechanism article, appearing again in a specific context. Every mechanistic finding for BPC-157 has the same shape: a measurable effect on a known pathway, with no established route from the peptide to that pathway. The findings accumulate without converging.

How growth-factor claims should be read

Growth-factor language carries strong connotations of tissue building and repair, and it is easy for a reported interaction to be presented as a demonstrated growth effect. The reported observations concern signalling components in model systems. They are not evidence of growth, repair or regeneration in an organism.

What would change the picture

A molecular target for the peptide. That would convert every downstream observation from a floating association into a position in a defined pathway, and would make the growth-factor findings interpretable. It remains the single most valuable missing piece in this compound's characterisation.

Frequently asked questions

Does BPC-157 act on growth hormone receptors?: Effects related to growth hormone receptor expression have been reported in tendon fibroblast work. Whether that is an initiating event or downstream of something else is not established.
Why is the absence of a receptor such a problem?: Without knowing where the compound acts first, any downstream finding is a position in a chain of unknown length rather than a mechanism.
Does this mean BPC-157 promotes growth?: No. The observations concern signalling components in model systems, not growth or repair in an organism.

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound', the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it. Different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Growth Factor Signalling in the BPC-157 Literature